Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
3.84 ^USD	+5.21%		+14.29%	0.00%

May. 15	Transcript : Acumen Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:55 AM
May. 14	Transcript : Acumen Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024

Acumen Pharmaceuticals, Inc. Announces Resignation of Dr. Jeffrey Sevigny to Its Board of Directors

August 15, 2022 at 04:36 pm EDT

Acumen Pharmaceuticals, Inc. announced the resignation Dr. Jeffrey Sevigny notified the Board of Directors of his resignation from the Board of Directors, effective immediately. Dr. Sevigny's departure was due to requirements of his current employment and not due to any disagreement with the Company.

Latest news about Acumen Pharmaceuticals, Inc.

Transcript : Acumen Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:55 AM	May. 15
Transcript : Acumen Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study	May. 08	MT
Acumen Pharmaceuticals, Inc. Announces First Patient Dosed in Altitude-Ad, A Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer?S Disease	May. 08	CI
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	Apr. 04	MT
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	Apr. 04	MT
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	Apr. 04	CI
Acumen Pharmaceuticals Files $200 Million Mixed Shelf	Mar. 27	MT
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Transcript : Acumen Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Acumen Pharmaceuticals, Inc. Presents Sabirnetug Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting	Mar. 08	CI
Acumen Pharmaceuticals, Inc. Appoints James Doherty as Its President and Chief Development Officer	Feb. 01	CI
Transcript : Acumen Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM	Jan. 11
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Deutsche Bank Initiates Coverage on Acumen Pharmaceuticals With Buy Rating, $8 Price Target	Dec. 12	MT
Acumen Pharmaceuticals Secures $50 Million Credit Facility	Nov. 13	MT
Transcript : Acumen Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures	Nov. 13	CI
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding	Nov. 12	CI
Transcript : Acumen Pharmaceuticals, Inc. Presents at UBS Biopharma Conference 2023, Nov-09-2023 10:00 AM	Nov. 09
Halozyme Therapeutics Signs Non-Exclusive License Deal With Acumen Pharmaceuticals for Enhanze Technology	Nov. 06	MT
Acumen Pharmaceuticals, Inc. Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease	23-10-27	CI

Chart Acumen Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimerâs pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.84 USD

Average target price

12.8 USD

Spread / Average Target

+233.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACUMEN PHARMACEUTICALS, INC.	0.00%	231M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.62%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research